What the FDA labels say about taking them together
Ibrutinib and voriconazole
Ibrutinib's FDA label of October 21, 2025 names voriconazole in its drug interactions section, and voriconazole's label names ibrutinib too. The voriconazole label: “Avoid concomitant use of VFEND. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended. Refer to the prescribing information for the relevant product.”
Check it at the source: the ibrutinib FDA label on DailyMed (effective October 21, 2025); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the ibrutinib label say about voriconazole?
Ibrutinib label, drug interactionsDose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors [see Dosage and Administration ( 2.3 )].
Source: FDA drug label (Imbruvica), Pharmacyclics LLC, effective October 21, 2025 (SPL set 0dfd0279-ff17-4ea9-89be-9803c71bab44), via openFDA; the full label on DailyMed
What does the voriconazole label say about ibrutinib?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Prevention or Management Recommendations: Avoid concomitant use of VFEND. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended. Refer to the prescribing information for the relevant product.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ibrutinib | Voriconazole | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once